Filing Flows › Adaptive Biotechnologies (ADPT) › Who owns the stock
Who owns Adaptive Biotechnologies (ADPT) stock
282 funds reported Adaptive Biotechnologies (ADPT) shares in their latest 13F filings, worth $3.5B in all. The largest holder is Viking Global Investors LP ($643M). Last quarter 137 funds added to their stakes and 122 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Viking Global Investors LP | 29,993,708 | $643M | unchanged | 2026-06-30 |
| BlackRock | 15,139,159 | $325M | increase | 2026-06-30 |
| Vanguard Group | 11,282,152 | $183M | increase | 2025-12-31 |
| Vanguard Capital Management LLC | 6,403,587 | $137M | increase | 2026-06-30 |
| Wellington Management Group LLP | 5,911,366 | $127M | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 5,476,231 | $117M | increase | 2026-06-30 |
| D. E. Shaw | 4,625,859 | $99.2M | increase | 2026-06-30 |
| Westfield Capital Management Co LP | 4,267,645 | $91.5M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 3,641,837 | $78.1M | increase | 2026-06-30 |
| State Street | 3,458,388 | $74.2M | increase | 2026-06-30 |
| Invesco | 3,094,011 | $66.4M | decrease | 2026-06-30 |
| Goldman Sachs Group | 2,984,227 | $64.0M | decrease | 2026-06-30 |
| Price T Rowe Associates | 2,665,308 | $57.2M | increase | 2026-06-30 |
| Driehaus Capital Management LLC | 2,527,703 | $54.2M | increase | 2026-06-30 |
| Arrowstreet Capital, Limited Partnership | 2,524,620 | $54.2M | increase | 2026-06-30 |
Adaptive Biotechnologies' latest quarter
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ADPT stock?
By the latest 13F filings: Viking Global Investors LP ($643M); BlackRock ($325M); Vanguard Group ($183M); Vanguard Capital Management LLC ($137M); Wellington Management Group LLP ($127M).
What is the short interest in ADPT?
11,991,988 shares were sold short at the 2026-10-15 settlement, 1.25% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.